Literature DB >> 23018470

Inter-individual differences in baseline coagulation activities and their implications for international normalized ratio control during warfarin initiation therapy.

Yosuke Ichimura1, Harumi Takahashi, Michael T M Lee, Mari Shiomi, Kiyoshi Mihara, Takashi Morita, Yuan-Tsong Chen, Hirotoshi Echizen.   

Abstract

BACKGROUND AND
OBJECTIVE: Genetic polymorphisms of cytochrome P450 (CYP) 2C9 (CYP2C9) and vitamin K epoxide reductase complex subunit 1 (VKORC1) and patient demographic characteristics are responsible for inter-individual differences in warfarin maintenance dosage requirements. At present, however, the factors associated with over-anticoagulation responses, especially before achieving the maintenance phase, have not been completely clarified. In this study, we investigated the effects of baseline coagulation activity assessed in terms of the level of fully carboxylated plasma normal prothrombin (NPT) on international normalized ratio (INR) control during the induction phase of warfarin therapy. Our objectives were to (1) identify factors associated with inter-patient variability in baseline NPT (NPT(0)); (2) estimate the therapeutic NPT (NPT(tx)) levels that can achieve an INR of 2-3; and (3) investigate the influence of NPT(0) on the INR response to warfarin by employing modelling and simulation techniques.
METHODS: We measured NPT before (NPT(0)) and during the introduction of warfarin therapy for up to 3 months and analysed functional single nucleotide polymorphisms (SNPs) of VKORC1 and CYP4F2 in 179 Chinese patients. The patients were classified into tertile groups according to NPT(0) values (i.e. high, intermediate and low groups), and in each group the NPT(tx) achieving therapeutic INR, the absolute reduction of NPT from NPT(0) to NPT(tx), and the percentage inhibition of NPT(0) [{(NPT(0) - NPT(tx))/NPT(0)} × 100] were obtained. The nonlinear relationship between NPT and INR was modelled on the basis of the INR value before warfarin treatment (INR(0)) added by the nonlinear increase in INR after warfarin initiation, which was predicted using the percentage inhibition of NPT(0) and a nonlinear coefficient (λ). The population parameter λ and its inter-individual variability and intra-individual variability in INR in the NPT-INR model were estimated by nonlinear mixed-effect modelling software NONMEM(®).
RESULTS: Multivariate analysis identified age and liver disease as covariates of NPT(0), but none of the SNPs had a significant influence. Although the mean absolute NPT reduction necessary to achieve NPT(tx) was dependent on NPT(0) (i.e. the higher the NPT(0), the larger the reduction in NPT), the percentage inhibition was within the narrow range of 67-72 % of NPT(0), irrespective of NPT(0). However, a significantly higher percentage inhibition (80 % on average) was observed in patients with INR values exceeding 4.0. As the nonlinear coefficient λ in the developed model was dependent on NPT(0) (i.e. the higher the NPT(0), the larger the nonlinear λ value), the simulated nonlinear NPT-INR curves were superimposable in the three respective NPT(0) groups, and the only difference was the starting median NPT(0) level. As a result, a steeper increase in the slope of the nonlinear NPT-INR curve might be expected in patients with a lower NPT(0) after initiation of warfarin.
CONCLUSIONS: The present study suggests that INR may be prolonged by warfarin nonlinearly as a function of the percentage inhibition of NPT(0). Furthermore, these results indicate that NPT(0) may contribute to inter-individual variability in the INR response, and that patients with low NPT(0) may have the potential to show a sharp increase in INR during initiation therapy with warfarin.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23018470     DOI: 10.1007/s40262-012-0009-6

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  24 in total

1.  CA-1 method, a novel assay for quantification of normal prothrombin using a Ca2+ -dependent prothrombin activator, carinactivase-1.

Authors:  D Yamada; T Morita
Journal:  Thromb Res       Date:  1999-05-15       Impact factor: 3.944

2.  Integration of genetic, clinical, and INR data to refine warfarin dosing.

Authors:  P Lenzini; M Wadelius; S Kimmel; J L Anderson; A L Jorgensen; M Pirmohamed; M D Caldwell; N Limdi; J K Burmester; M B Dowd; P Angchaisuksiri; A R Bass; J Chen; N Eriksson; A Rane; J D Lindh; J F Carlquist; B D Horne; G Grice; P E Milligan; C Eby; J Shin; H Kim; D Kurnik; C M Stein; G McMillin; R C Pendleton; R L Berg; P Deloukas; B F Gage
Journal:  Clin Pharmacol Ther       Date:  2010-04-07       Impact factor: 6.875

3.  A PK-PD model for predicting the impact of age, CYP2C9, and VKORC1 genotype on individualization of warfarin therapy.

Authors:  A-K Hamberg; M-L Dahl; M Barban; M G Scordo; M Wadelius; V Pengo; R Padrini; E N Jonsson
Journal:  Clin Pharmacol Ther       Date:  2007-02-14       Impact factor: 6.875

4.  Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra- and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African-Americans.

Authors:  Harumi Takahashi; Grant R Wilkinson; Edith A Nutescu; Takashi Morita; Marylyn D Ritchie; Maria G Scordo; Vittorio Pengo; Martina Barban; Roberto Padrini; Ichiro Ieiri; Kenji Otsubo; Toshitaka Kashima; Sosuke Kimura; Shinichi Kijima; Hirotoshi Echizen
Journal:  Pharmacogenet Genomics       Date:  2006-02       Impact factor: 2.089

5.  Laboratory and clinical outcomes of pharmacogenetic vs. clinical protocols for warfarin initiation in orthopedic patients.

Authors:  P A Lenzini; G R Grice; P E Milligan; M B Dowd; S Subherwal; E Deych; C S Eby; C R King; R M Porche-Sorbet; C V Murphy; R Marchand; E A Millican; R L Barrack; J C Clohisy; K Kronquist; S K Gatchel; B F Gage
Journal:  J Thromb Haemost       Date:  2008-07-24       Impact factor: 5.824

6.  VKORC1 haplotypes are associated with arterial vascular diseases (stroke, coronary heart disease, and aortic dissection).

Authors:  Yibo Wang; Weili Zhang; Yuhui Zhang; Yuejin Yang; Lizhong Sun; Shengshou Hu; Jilin Chen; Channa Zhang; Yi Zheng; Yisong Zhen; Kai Sun; Chunyan Fu; Tao Yang; Jianwei Wang; Jing Sun; Haiying Wu; Wayne C Glasgow; Rutai Hui
Journal:  Circulation       Date:  2006-03-20       Impact factor: 29.690

7.  A warfarin induction regimen for out-patient anticoagulation in patients with atrial fibrillation.

Authors:  R C Tait; A Sefcick
Journal:  Br J Haematol       Date:  1998-06       Impact factor: 6.998

8.  Warfarin treatment in patients with atrial fibrillation: observing outcomes associated with varying levels of INR control.

Authors:  Christopher Ll Morgan; Phil McEwan; Andrzej Tukiendorf; Paul A Robinson; Andreas Clemens; Jonathan M Plumb
Journal:  Thromb Res       Date:  2008-12-04       Impact factor: 3.944

9.  A randomized controlled trial of genotype-based Coumadin initiation.

Authors:  James K Burmester; Richard L Berg; Steven H Yale; Carla M Rottscheit; Ingrid E Glurich; John R Schmelzer; Michael D Caldwell
Journal:  Genet Med       Date:  2011-06       Impact factor: 8.822

10.  Estimation of the warfarin dose with clinical and pharmacogenetic data.

Authors:  T E Klein; R B Altman; N Eriksson; B F Gage; S E Kimmel; M-T M Lee; N A Limdi; D Page; D M Roden; M J Wagner; M D Caldwell; J A Johnson
Journal:  N Engl J Med       Date:  2009-02-19       Impact factor: 91.245

View more
  1 in total

1.  Determinants of the over-anticoagulation response during warfarin initiation therapy in Asian patients based on population pharmacokinetic-pharmacodynamic analyses.

Authors:  Minami Ohara; Harumi Takahashi; Ming Ta Michael Lee; Ming-Shien Wen; Tsong-Hai Lee; Hui-Ping Chuang; Chen-Hui Luo; Aki Arima; Akiko Onozuka; Rui Nagai; Mari Shiomi; Kiyoshi Mihara; Takashi Morita; Yuan-Tsong Chen
Journal:  PLoS One       Date:  2014-08-22       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.